Polycythemia vera and essential thrombocythemia are the most common ... that might be caused by exposure to cytotoxic drugs. A risk-oriented approach is employed for stratifying patients to ...

Additional testing may be ordered to determine the cause (e.g., anemia, inflammations, cancer), which may require treatment. Less common essential thrombocythemia is a high platelet count caused ...

Among patients with essential thrombocythemia (ET), treatment with ropeginterferon alfa-2b-njft (P1101) generated durable hematologic responses with a manageable safety profile and a lower rate of ...

In the SURPASS-ET trial, the company weighed its treatment, dubbed P1101 in the study, against platelet-reducing anagrelide as a second-line therapy for patients with essential thrombocythemia (ET).

• Hgb > 18.5 g/dl (men) or > 16.5 g/dl (women) or Hgb or Hct > 99th percentile of method-specific reference range for age, sex or altitude of residence or Hgb > 17 g/dl (men) or > 15 g/dl (women ...